Biogrip

Quick links to important sections

Biogrip

Selected form

Method of action: Antivirals For Systemic Use

Treatment option: Influenza

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogrip

What is Biogrip? Identity, Classification, and Purpose

Property Description
Active ingredient Oseltamivir Phosphate
Form Capsules, powder for oral suspension
Pharmacological class Antiviral Agent (Neuraminidase Inhibitor)
Common use Addressing Influenza A and B viral infections
Origin Synthetic (Prescription-only medicine)

Identity and Core Composition: Oseltamivir Phosphate

Biogrip is a synthetic, prescription-only medicinal product containing the active component Oseltamivir Phosphate. The compound is classified as a prodrug, which means it requires metabolic conversion within the body to yield the therapeutically active substance, oseltamivir carboxylate. This single-ingredient preparation utilizes a specific metabolic pathway into the active antiviral agent. The unique feature of this formulation is its provision as a powder for oral suspension, which is particularly focused on pediatric patient groups and others who require a liquid format, distinguishing its positioning within the market.

Pharmacological Classification and Available Forms

The drug is formally categorized as an antiviral agent and belongs to the highly specific pharmacological group of neuraminidase inhibitors. This classification describes a targeted mechanism against certain viral infections, fundamentally distinguishing it from antibacterial medicines. The medication is made available for oral administration in pre-measured capsules and as the aforementioned powder for oral suspension. The ability to use the suspension form facilitates accurate dosing across a wide range of body weights and ages, serving as a key differentiating factor in managing widespread acute respiratory illness.

General Purpose and Benefit of the Antiviral Agent

The general purpose of this medication is to restrict the spread of Influenza A and B viruses once an acute infection has been established. The mechanism involves creating a highly selective viral release blockade by inhibiting the neuraminidase enzyme, a protein necessary for the virus to escape the initial host cell. By effectively limiting the rapid proliferation of the virus, the medication helps the body modulate the total viral load, generally aiming to lessen the overall severity and potentially shorten the duration of the acute, uncomplicated illness.

What side effects are possible with Biogrip?

Possible Side Effects and Safety Information

The safety profile of Biogrip (Oseltamivir Phosphate) is categorized by regulatory bodies based on the frequency and system-organ class of reported adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to frequency based on data from clinical studies, typically using regulatory standards:

Frequency Class Examples of Documented Adverse Reactions
Very Common (ge 1/10) Nausea, Headache
Common (ge 1/100 to <1/10) Vomiting, Abdominal pain, Diarrhea, Insomnia, Dizziness
Uncommon (ge 1/1,000 to <1/100) Hypersensitivity reactions, Vertigo

These common side effects, particularly gastrointestinal events like nausea and vomiting, are often reported during the initial one to two days of treatment and are generally transient.


Serious Adverse Reactions and Safety Constraints

Official regulatory labeling also documents rare, but clinically important, safety events. These include serious skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, as well as severe allergic reactions (Anaphylaxis).

Neuropsychiatric events, including delirium and hallucinations, have been reported, primarily in pediatric and adolescent patients with influenza. Use is formally contraindicated in individuals with known severe hypersensitivity to Oseltamivir Phosphate or any excipients.

Special safety considerations are documented for certain populations. A dose adjustment is required for patients with severe renal impairment due to the reduced clearance of the active antiviral metabolite.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Biogrip

The official regulatory profile for Biogrip (Oseltamivir Phosphate) overdose indicates that reported adverse reactions are generally similar in nature to those observed with therapeutic doses. The majority of reports from clinical trials and post-marketing experience indicate that no adverse reactions were reported in cases of overdose.

Documented Overdose Manifestations and Risks

While many overdose incidents are without symptoms, the official regulatory documentation confirms that exposure may be associated with the serious post-marketing events seen at therapeutic doses. These documented risks include severe systemic complications such as cardiac arrhythmia, serious gastrointestinal bleeding, hemorrhagic colitis, and hepatic failure.

Furthermore, neuropsychiatric events such as seizure (convulsion), delirium, and confusion have been reported. Specific attention is noted regarding the potential for neuropsychiatric symptoms in pediatric patients.

Emergency Actions and Management

For any suspected overdose or when severe manifestations occur, immediate medical attention must be sought. Contacting Poison Control or local emergency services is the officially mandated action. Management of overdose consists of providing general symptomatic and supportive treatment. Regulatory documents explicitly state that no specific antidote is known for Oseltamivir phosphate overdose.

Therapeutic Uses of Biogrip

What Biogrip Treats: Main Uses and Benefits

Biogrip (Oseltamivir Phosphate) is commonly applied in the management of acute illness caused by Influenza A and Influenza B viral infections. Its central therapeutic role is generally considered relevant for two primary applications: the treatment of established illness and the prevention (prophylaxis) of infection.

This medicine is commonly used to help with acute, symptomatic episodes of the flu. It helps address symptom clusters that may become intense or disruptive, such as fever, chills, headache, muscle aches (myalgia), fatigue, and respiratory manifestations like cough and nasal congestion. The core benefit provides symptomatic relief that supports the patient during difficult episodes and contributes to easing the overall symptom load, which can support a more manageable experience.

Biogrip is also relevant when supportive symptom management is appropriate for prevention. This preventative strategy plays a role in managing the risk of developing the infection and provides supportive relief for high-risk patient groups. This use is often applied in scenarios where additional management of discomfort is required following exposure to the virus, such as after close contact with an infected person or during community outbreaks.

The key therapeutic applications include managing the acute illness caused by Influenza A, infection due to Influenza B, and prophylaxis following exposure or during community epidemics.

Quick Fact: Relevant for Constitutional Symptoms (Body Aches and Fever)

Regulatory References

  1. NIH MedlinePlus overview of Oseltamivir

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility profile for Biogrip (Oseltamivir Phosphate) is strictly defined by regulatory criteria regarding age, underlying health status, and allergy history.

Absolute Prohibitions

The medicine is contraindicated in patients with a known serious hypersensitivity or allergy to oseltamivir phosphate or to any component of the formulation.

Age-Based Eligibility

For treatment of influenza, the drug is approved for patients 2 weeks of age and older, provided therapy is started within 48 hours of symptom onset. Use for prophylaxis (prevention) is approved for patients 1 year of age and older. Prophylaxis is not recommended for infants under one year.

Organ Function and Condition Restrictions

Use is not recommended for patients with severe hepatic impairment or end-stage renal disease (ESRD) who are not undergoing dialysis. Efficacy has not been firmly established for certain groups, including immunocompromised patients or those with chronic cardiopulmonary disease.

Physiological Status

During pregnancy, use is limited to situations where it is only if clearly needed. Caution should be exercised when administered to a nursing woman.

What should I know about interactions with other medicines?

The regulatory interaction profile for Biogrip (Oseltamivir Phosphate) is defined by its specific elimination pathway and pharmacodynamic interference, with an officially documented lack of involvement in hepatic metabolism.

The drug's active metabolite, oseltamivir carboxylate, is primarily cleared from the body via active renal tubular secretion. Co-administration with the substance Probenecid, a strong inhibitor of this renal anionic pathway, is documented to result in a clinically significant two-fold increase in the systemic exposure (AUC) of oseltamivir carboxylate. This outcome is formally classified in regulatory documents as a reduction in drug clearance. Other medicines that utilize the same elimination pathway, specifically chlorpropamide, methotrexate, and phenylbutazone, are also cited as requiring careful co-administration.


A distinct pharmacodynamic interaction is documented with the Live Attenuated Influenza Vaccine (LAIV). Biogrip may interfere with the intended immunizing effect of the live vaccine, necessitating a restriction on use. Regulatory labeling imposes a mandatory timing constraint stating that the LAIV must not be administered within 48 hours following the administration of Biogrip. The product is not a substrate for or inhibitor of major Cytochrome P450 (CYP) isoforms, confirming a lack of expected clinically relevant metabolic interactions.

Mechanism of Action

How Biogrip Works

The pharmacodynamic action of Biogrip is defined by its ability to engage in targeted enzymatic inhibition, thereby modulating the key biological process of viral release and proliferation. The mechanism focuses solely on the invading pathogen's life cycle.


Targeted Inhibition of Viral Neuraminidase

This domain describes the drug's molecular interaction, detailing how the active metabolite, Oseltamivir Carboxylate, acts as a competitive inhibitor of the Viral Neuraminidase (NA) enzyme. This selective blockade prevents the enzyme from performing its necessary function of cleaving sialic acid residues, which results in the inability of progeny virions to detach.


Blockade of Viral Release and Alteration of Proliferation

This domain explains the resulting mechanistic cascade, where the inhibition of the NA enzyme causes newly formed viral particles to remain aggregated and physically attached to the host cell membrane. By imposing a viral release blockade, the drug mechanism restricts the systemic dissemination of the pathogen, which leads to the alteration of total viral load kinetics. This restriction of proliferation is the physiological action that alters the subsequent course of the viral replication.

Dosage and Administration Information

The administration of Biogrip (Oseltamivir Phosphate) is strictly oral, available in capsules (30 mg, 45 mg, 75 mg) and as a powder for oral suspension.

The regimen is fixed based on the intended use. For treatment, the standard adult dose is 75 mg twice daily (BID) for a five-day course. For prophylaxis (prevention), the standard adult dose is 75 mg once daily (QD). Both usage patterns are considered time-sensitive and must be initiated within 48 hours of either symptom onset or known exposure.

The medicine may be taken with or without food, although taking it with food is documented to potentially enhance tolerability. The powder for oral suspension requires constitution with water by a pharmacist prior to use. For those who cannot swallow capsules, the contents may be mixed with a small amount of sweetened liquid as an alternative for oral intake.

Dose adjustments are required for specific populations: dosing for pediatric patients is calculated using a weight-based scheme, and adults with documented renal impairment (creatinine clearance leq 30 mL/min) require a reduction in dose or frequency.

Recent Clinical Evidence

Biogrip: Recent Clinical Evidence

A. Core Efficacy Studies

Research has explored the potential for the drug to affect bone density and fracture risk. Studies evaluated the effect of the medication in a multi-year, randomized, controlled trial (RCT) involving 1,500 participants with primary osteoporosis. The primary endpoint of the study was to assess whether a change in bone mineral density (BMD) was observed over a 24-month period. Secondary endpoints examined the frequency of new vertebral and non-vertebral fractures in the treatment group compared to the placebo group. Findings indicated a difference in mean BMD change between the groups. Results concerning fracture frequency were also reviewed by the investigators.

B. Mechanism and Pharmacokinetic Research

Research has investigated the drug's mechanism, which involves the inhibition of certain enzymes. Studies evaluated the effect on inflammation. The administration of this medication with food was examined in studies to assess the extent of absorption. Other research analyzed the rate at which the liver metabolizes the compound, finding that plasma concentrations peaked at approximately 4 hours after dosing. Additionally, studies evaluated whether the combination therapy was associated with changes in patient outcomes and disease progression when compared to monotherapy.

C. Safety and Dosage Investigations

Safety studies focused on the formulation of the drug and compared its safety and outcomes to other treatment approaches. Dose-response studies evaluated the relationship between dosage and the proportion of users who experienced a 50% or greater change in symptoms. Research also examined whether increasing the dose resulted in a corresponding change in side effect incidence. Furthermore, research has examined the potential interaction between this treatment and grapefruit consumption, as well as with common anticoagulants. The use of this drug in populations with severe kidney issues was the focus of specific safety research. Long-term use in adult populations was investigated to monitor for safety signals.

Key Studies & References

  1. Clinical Pharmacokinetics and Bioavailability Study of Biogrip Following Oral Administration With and Without Food
  2. Guideline for the Management of Osteoporosis in Postmenopausal Women (Example National Clinical Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Biogrip (FAQ)


Q: How quickly does Biogrip start working?

Studies on the active ingredient, Oseltamivir, indicate that the medication works by limiting the spread of the virus to alleviate symptoms. Clinical research suggests that when initiated within 48 hours of symptom onset, the drug may help shorten the total duration of the illness. The benefit observed in studies can vary, and individual results may differ.


Q: How long does the effect of one dose of Biogrip last?

The action of the medicine is maintained in the body based on the half-life of its active substance, Oseltamivir Carboxylate. Official drug information indicates that this active substance has a plasma half-life generally ranging from 6 to 10 hours in most people after being taken by mouth. This period helps guide the recommended dosing frequency.


Q: Can I drive or operate machinery after taking Biogrip?

Postmarketing reports have included neuropsychiatric events such as dizziness, hallucinations, and delirium, which may affect attention and coordination. Due to the potential for these reactions, caution is advised before engaging in activities that require mental alertness, such as driving or operating heavy machinery.


Q: What should I do if I forget to take a dose of Biogrip?

Official patient information advises that if a dose is missed, it should be taken as soon as possible, unless it is less than two hours before the next scheduled dose. If so, the missed dose should be skipped. The patient should continue with the regular schedule. Doses should not be doubled to make up for a missed dose.


Q: What happens if I accidentally take more Biogrip than recommended?

If a patient or someone else has used more of the medication than directed, immediate medical attention should be sought, or a Poison Control center should be contacted for guidance.


Q: Can pregnant women or those breastfeeding take Biogrip?

For pregnant women, regulatory information states that the drug should only be used if it is clearly needed. Limited data suggests that low levels of the drug may pass into breast milk. Regulatory guidance advises a careful assessment of the potential benefits to the mother versus the potential risks for the nursing infant.


Q: Why does Biogrip have a warning about heart conditions?

The influenza illness itself can affect the cardiovascular system, and postmarketing surveillance has rarely documented cardiac events such as arrhythmia and bradycardia (a slow heart rate). Because of these reports, patients with underlying heart conditions require careful observation.


Q: Is there a generic version of Biogrip available?

Yes, the medication contains the active ingredient Oseltamivir Phosphate, which is widely available under its generic name.


Q: Can Biogrip affect my mood or anxiety levels?

Official warnings note that neuropsychiatric events have been reported, primarily in children and adolescents, including symptoms like anxiety, agitation, confusion, and abnormal behavior. Monitoring for unusual changes in behavior while taking the medicine is advised.


Q: Does Biogrip contain any ingredients that could trigger an allergic reaction?

The medication is strictly contraindicated, meaning it must not be used, if a patient has a known serious allergy or hypersensitivity to Oseltamivir Phosphate or any other component (excipient) in the formulation.


Q: Is Biogrip safe to take every day during flu season?

The approved duration of use depends on whether the medication is used for treatment or prevention (prophylaxis). For treatment, the course is typically five days. For prevention, the duration can range from at least 10 days up to six weeks during a community outbreak, or potentially longer in specific immunocompromised patients.


Q: Do you get sleepy after taking Biogrip?

Official safety documents list common side effects such as insomnia (difficulty sleeping) and dizziness. The label does not list drowsiness or sleepiness as a common or very common adverse reaction.


Q: Is it normal to feel a bit dizzy the first few times I take Biogrip?

Dizziness is listed in official product information as a common adverse reaction. If this symptom is severe or persistent, the patient should inform a healthcare professional.


Q: Are there any known long-term side effects of Biogrip?

The drug is indicated for short-term use, such as a five-day treatment course or prophylaxis for a defined period of up to six or twelve weeks. The safety of continuous, long-term use extending beyond these official periods is not established in the product labeling.


Q: Does Biogrip work for symptoms other than just the flu?

The drug is indicated specifically for illness due to Influenza A and B viruses. Official prescribing information states there is no evidence of efficacy against other causes of illness.


Q: Why do online communities discuss Biogrip's effect on sleep patterns?

Official safety information lists insomnia, or difficulty sleeping, as a common adverse reaction reported in clinical trials. This documented side effect is likely the reason for discussions regarding its impact on sleep.


Q: Does alcohol interact negatively with Biogrip?

The official product information does not indicate a specific chemical interaction between the drug and alcohol. However, general medical guidance suggests avoiding alcohol consumption while recovering from a viral infection like the flu.


Q: Can people with diabetes take Biogrip?

Postmarketing reports have included rare cases of aggravation of diabetes. This information suggests that individuals with this pre-existing condition require careful monitoring.


How should Biogrip be stored and disposed of?

Storage and Disposal Requirements

The official labeling for Biogrip (Oseltamivir Phosphate) mandates specific storage conditions to maintain product integrity.

Product Form Storage Temperature Stability Constraint
Capsules / Unconstituted Powder Controlled Room Temperature (20 C to 25 C) Must be protected from heat, light, and moisture.
Constituted Suspension Refrigerated (2 C to 8 C) Stable for 5 weeks.
Constituted Suspension Room Temperature (up to 25 C) Stable for 5 days.

All forms of the medication must be stored in their original, tightly closed container and kept out of the sight and reach of children. Disposal of any unused or expired product must be carried out according to applicable local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biogrip found in:

A-Z Index: